title: [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics].
abstract: HER2-targeted therapy for HER2-positive breast cancer is one of the success stories in medical oncology. Trastuzumab, a humanized monoclonal antibody, was the first approved HER2-targeted agent. Subsequent developments include agents with different mechanisms, such as lapatinib, a tyrosine kinase inhibitor. We describe here the results of late-phase clinical trials of two newly-available anti-HER2 agents, T-DM1 and pertuzumab.
authors.affiliation: Division of Breast and Medical Oncology, National Cancer Center Hospital, Japan.
authors.forename: Emi
authors.initials: E
authors.lastname: Noguchi
authors.forename: Chikako
authors.initials: C
authors.lastname: Shimizu
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D006801:Humans; D008453:Maytansine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D015398:Signal Transduction; D000068878:Trastuzumab
chemical_list: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human; C485206:pertuzumab